1. Sakane T, Takeno M, Suzuki N, Inaba G. Behc¸et's disease. N Engl J Med. 1999;341(17):1284–91.
2. International Study Group for Behc¸et's Disease. Criteria for diag- nosis of Behc¸et's disease. Lancet. 1990;335(8697):1078–80.
3. Kirino Y, Bertsias G, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Genome-wide association analysis identifies new susceptibility loci for Behc¸et's disease and epistasis between HLA-B*51 and ERAP1. Nat Genet. 2013;45(2):202–7.
4. Meguro A, Inoko H, Ota M, Katsuyama Y, Oka A, Okada E, et al. Genetics of Behc¸et disease inside and outside the MHC. Ann Rheum Dis. 2010;69(4):747–54.
5. Mizuki N, Meguro A, Ota M, Ohno S, Shiota T, Kawagoe T, et al. Genome-wide association studies identify IL23R-IL12RB2 and IL10 as Behc¸et's disease susceptibility loci. Nat Genet. 2010;42(8):703–6.
6. Lee YJ, Horie Y, Wallace GR, Choi YS, Park JA, Choi JY, et al. Genome-wide association study identifies GIMAP as a novel susceptibility locus for Behcet's disease. Ann Rheum Dis. 2013;72(9):1510–6.
7. Remmers EF, Cosan F, Kirino Y, Ombrello MJ, Abaci N, Satorius C, et al. Genome-wide association study identifies var- iants in the MHC class I, IL10, and IL23R-IL12RB2 regions asso- ciated with Behc¸et's disease. Nat Genet. 2010;42(8):698–702.
8. Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, et al. Dense genotyping of immune-related loci impli- cates host responses to microbial exposure in Behcet's disease susceptibility. Nat Genet. 2017;49(3):438–43.
9. Kirino Y, Zhou Q, Ishigatsubo Y, Mizuki N, Tugal-Tutkun I, Seyahi E, et al. Targeted resequencing implicates the familial Mediterranean fever gene MEFV and the toll-like receptor 4 gene TLR4 in Behc¸et disease. Proc Natl Acad Sci USA. 2013;110(20):8134–9.
10. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Altunbas HH, Urgancioglu M. Uveitis in Behcet disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138(3):373–80.
11. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behc¸et's disease. Int J Dermatol. 2003;42(5):346–51.
12. Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, et al. Clinical features and natural course of Behc¸et's disease in 661 cases: a multicentre study. Br J Dermatol. 2007;157(5): 901–6.
13. de Menthon M, Lavalley MP, Maldini C, Guillevin L, Mahr A. HLA-B51/B5 and the risk of Behcet's disease: a systematic review and meta-analysis of case-control genetic association studies. Arthritis Rheum. 2009;61(10):1287–96.
14. Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's dis- ease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5): 887–900.
15. Sun A, Hsieh RP, Chu CT, Wang JT, Liu BY, Chiang CP. Some specific human leukocyte antigen (HLA)-DR/DQ haplotypes are more important than individual HLA-DR and -DQ phenotypes for the development of mucocutaneous type of Behcet's disease and for disease shift from recurrent aphthous stomatitis to mucocutaneous type of Behcet's disease. J Oral Pathol Med. 2001;30(7):402–7.
16. Baris S, Akyurek O, Dursun A, Akyol M. The impact of the IL- 1b, IL-1Ra, IL-2, IL-6 and IL-10 gene polymorphisms on the development of Behcet's disease and their association with the phenotype. Med Clin (Barc). 2016;146(9):379–83.
17. Altenburg A, Papoutsis NG, Krause L, Zouboulis CC. Association between HLA class I phenotypes and clinical mani- festations in Adamantiades-Behcet disease patients in Germany. Clin Exp Rheumatol. 2008;26(4):S7.
18. Hatemi G, Fresko I, Tascilar K, Yazici H. Increased enthesopathy among Behc¸et's syndrome patients with acne and arthritis: an ultrasonography study. Arthritis Rheum. 2008;58(5):1539–45.
19. Tascilar K, Melikoglu M, Ugurlu S, Sut N, Caglar E, Yazici H. Vascular involvement in Behcet's syndrome: a retrospective ana- lysis of associations and the time course. Rheumatology (Oxford). 2014;53(11):2018–22.
20. Karaca M, Hatemi G, Sut N, Yazici H. The papulopustular lesion/arthritis cluster of Behcet's syndrome also clusters in fami- lies. Rheumatology (Oxford). 2012;51(6):1053–60.
21. Japanese Ministry of Health, Labour and Welfare. Statutory intractable diseases implemented on 1 January 2015; 2015 [Japanese]. Available from: http://www.mhlw.go.jp/stf/seisakunit- suite/bunya/0000062437.html [last accessed 30 Dec 2016].
22. Ministry of Health, Labour and Welfare, Japan. Ethical Guidelines for Medical and Health Research Involving Human Subjects; 2015. Available from: http://www.lifescience.mext.go.jp/files/pdf/n1500_01.pdf#search='Ethics+Review+Procedures+concerning+Research+with+Human+Subjects+published+in+2015+by+Ministry+of+Health%2C+Labour+and+Welfare-%2C+Japan' [last accessed 22 Nov 2016].
23. The International Criteria for Behcet's Disease (ICBD): a collab- orative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3): 338–47.
24. Tmoiiy IY, editor. Behc¸et's Disease. Tokyo: Springer; 2015. p. 1–20.
25. Takeuchi M, Kezuka T, Sugita S, Keino H, Namba K, Kaburaki T, et al. Evaluation of the long-term efficacy and safety of inflixi- mab treatment for uveitis in Behc¸et's disease: a multicenter study. Ophthalmology. 2014;121(10):1877–84.
26. Kirino Y, Ideguchi H, Takeno M, Suda A, Higashitani K, Kunishita Y, et al. Continuous evolution of clinical phenotype in 578 Japanese patients with Behcet's disease: a retrospective obser- vational study. Arthritis Res Ther. 2016;18(1):217.
27. Sanghvi C, Aziz K, Jones NP. Uveitis and the menstrual cycle. Eye (Lond). 2004;18(5):451–4.
28. Apaydin KC, Duranoglu Y, Ozgu€rel Y, Saka O. Serum prolactin levels in Behc¸et's disease. Jpn J Ophthalmol. 2000;44(4):442–5.
29. Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease. Cell Biochem Funct. 2006;24(4):353–6.
30. Mont'Alverne AR, Yamakami LY, Gonc¸alves CR, Baracat EC, Bonf´a E, Silva CA. Diminished ovarian reserve in Behc¸et's dis- ease patients. Clin Rheumatol. 2015;34(1):179–83.
31. Proenc¸a H, Ferreira C, Miranda M, Castanheira-Dinis A, Monteiro-Grillo M. Serum prolactin levels and Behc¸et disease. Eur J Ophthalmol. 2007;17(3):404–7.
32. Siroux V, Gonzalez JR, Bouzigon E, Curjuric I, Boudier A, Imboden M, et al. Genetic heterogeneity of asthma phenotypes identified by a clustering approach. Eur Respir J. 2014;43(2): 439–52.
33. Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40(4):769–74.